Talphera Termiini P/E

Mitä Talphera tekee? Talphera Inc, with ticker TLPH and ISIN US00444T2096, is a U.S.-based company headquartered in San Mateo, California, operating within the Health Care sector, specifically in the Pharmaceuticals industry. The company has 19 employees and went public via an IPO on February 11, 2011. Its website is https://www.acelrx.com. Talphera Inc is engaged in the development and commercialization of therapies designed for use in medically supervised settings. The company's product pipeline includes nafamostat-based candidates such as Niyad, which targets regional anticoagulants for injection into extracorporeal circuits during continuous renal replacement therapy for acute kidney injury patients and for chronic kidney disease patients undergoing hemodialysis. Another candidate, LTX-608, is a nafamostat formulation for direct intravenous infusion, intended for potential use as an antiviral treatment for conditions including COVID-19, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company is also developing two pre-filled syringes, Fedsyra and PFS-02, though specific details about these products are not provided. Talphera Inc focuses on advancing therapies for critical care applications within hospital and dialysis center environments. The company's operations are centered on pharmaceutical development and commercialization, with an emphasis on addressing unmet medical needs in specialized clinical settings. Talphera on yksi Eurpooliin suosituimmista yhtiöistä.